Navigation Links
Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
Date:11/28/2012

vancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications. The PEARL-SC Phase 2 study was designed as a randomized, double-blind, placebo-controlled, dose-ranging superiority trial to evaluate the safety, tolerability and efficacy of blisibimod plus standard of care, versus placebo plus standard of care. A total of 547 patients with active SLE were randomized to receive one of three different doses of blisibimod or placebo (100 mg weekly, 200 mg weekly or 200 mg monthly) administered subcutaneously over a minimum 24-week treatment period, in addition to standard-of-care therapy. The study was conducted at multiple centers worldwide. 

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended Se
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
2. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
3. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
4. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
5. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
6. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
7. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
9. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
10. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
11. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015 The breakthrough hepatitis C treatment, ... but manufacturer Gilead Sciences overcame initial market resistance through ... public relations campaigns. Sovaldi,s high cure rate, ... effects propelled the drug to $2.3 billion in sales ... quarter on the market. But Sovaldi,s price tag of ...
(Date:5/1/2015)... Calif. , May 1, 2015 Hitachi ... the United States launch of the ExoComplete™ ... fast and easy system for exosome collection to mRNA ... for Extracellular Vesicles ("ISEV") Annual Meeting, April 23 – ... Both products are intended for research use only of ...
(Date:5/1/2015)... , May 01, 2015 Research and Markets ... "Asian Dermatology Devices Market by Type, by End User ... The Asian Dermatology Devices market is estimated to grow ... China holds a larger share in the ... Japan . The Asian Dermatology Devices market holds ...
Breaking Medicine Technology:New Study Examines Success Lessons of Sovaldi's and Harvoni's Blockbuster Launches 2New Products for Exosome Isolation to mRNA Purification 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 3
... , WAYNE, N.J. and EMERYVILLE, Calif., Dec. 11 ... (Nasdaq: ONXX ) today announced results from ... trials were presented at the 32nd Annual San ... these studies evaluated Nexavar® (sorafenib) tablets in combination ...
... , , , LONDON and ... women with an aggressive form of breast cancer experienced a ... combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of ... presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer ...
Cached Medicine Technology:Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 2Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 3Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 4Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 5Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 6Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 7GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6
(Date:5/3/2015)... VEGAS and LOS ANGELES, American Telemedicine Association 2015 ... vitaphone e-health solutions, a full-service telemedicine ... launch of its new platform, VITA health services ... The VITA health services platform enables remote patient ... such as congestive heart failure (CHF), diabetes, COPD, ...
(Date:5/3/2015)... 03, 2015 “ BolehVPN ” was featured ... features the latest and coolest technology products available to consumers. ... conducted the review and shared with viewers how to protect ... these days is on computers and even more so online. ... meet people all over the world. In terms of work, ...
(Date:5/3/2015)... Hanover, MA (PRWEB) May 03, 2015 It is ... 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been ... of Lissa organized this great family-friendly event to honor her loving ... since its inception. , Just having turned 37, Lissa suffered ... Lissa passed away on August 24, 2012. This event is designed ...
(Date:5/2/2015)... 2015 Vancouver fencing company, QS Fencing, has ... advice to prospective clients related to their questions on railings ... railings around their decks and patios. While that seems like ... up once the person rolls up their sleeve to start ... railing in finding a gate that matches it. , Instead ...
(Date:5/2/2015)... 2015 We are pleased to announce ... Center as one of the Top Workplaces of 2015. ... addiction treatment field for their ethics and standards of ... to continue their educational efforts. The Delray Recovery Center ... forgetting their purpose – to help individuals heal from ...
Breaking Medicine News(10 mins):Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 3Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2
... rise in childhood obesity being blamed on the beverage ... substitute their sugary soft drinks// with low-calorie ... for a Healthier Generation. a joint initiative of the ... negotiated the plan with Cadbury Schweppes, Coca-Cola and PepsiCo ...
... have genetically modified mice in a study that would ... ,The research team was from the University of Texas ... results of the research were published in the journal Neuron. ... Pten in these mice.This gene has been known to be ...
... diagnostic tests for micro vascular cardiac disease on the lines ... be a good boost// to the researchers to develop novel ... afflict women much more than men. ,“Only in ... - a dysfunction of the heart’s small arteries - as ...
... food choices can play a crucial role in determining ... study // conducted by researchers at Boston University School ... The impact of this problem is more relevant in ... and healthy food is inadequate. ,‘What we ...
... competence of medical staff in the operating room, has ... and increased awareness regarding operating room safety. // Surprisingly, ... to teamwork. ,The survey, called the Safety ... questionnaire and applied to the health care environment. The ...
... sclerosis patients harbor immune cells that specifically overreact to ... mononucleosis. Although EBV has been suspected to play a ... had been largely unknown. ,Scientists think that ... with coordination and balance—is a result of the immune ...
Cached Medicine News:Health News:Nutritious Beverages to be Sold in School 2Health News:Micro vascular Disease Enabled with a Superior Test, Courtesy: Women’s Heart Progra 2Health News:Nurses Outsmart Surgeons When It Comes Safety And Team Wok 2Health News:Nurses Outsmart Surgeons When It Comes Safety And Team Wok 3Health News:EBV Might Trigger Multiple Sclerosis, Study 2Health News:EBV Might Trigger Multiple Sclerosis, Study 3Health News:EBV Might Trigger Multiple Sclerosis, Study 4
Shandon Laser MicroWriter is a laser labeling system developed specifically for anatomical pathology....
Eberbach's 2800 Series Micro Slide Cabinets provide safe, short-term and long-term, storage of prepared slides which can easily be indexed for retrieval. Cabinets are available in (2) two styles, a U...
Compact storage cabinets for 35 mm slides....
Fisherbrand* Micro Slide Cabinet is made of heavy gauge, reinforced steel....
Medicine Products: